Clinical Trial Update: An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients [Phase 2]

View source ↗

Summary

An open-label Phase 2 study evaluated telaprevir in combination with ribavirin and pegylated interferon for hepatitis C in stable liver transplant patients. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Incivek (telaprevir)
• PegIntron (pegylated interferon alfa-2b)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Hepatitis C | Phase 2 | Status: TERMINATED | Results posted: 2015-06-18